Advanced esophageal, stomach or lung cancer; MAGE-A4-specific humoral immune response in 4/20 patients, CD4+ and CD8+ T-cell responses in 3/20 and 6/20 patients. This evidence concerns the gene MAGEA4 and lung carcinoma.